Nutriband Inc. announced the completion of the commercial manufacturing process scale-up for its lead product, AVERSA™ Fentanyl, with Kindeva Drug Delivery. AVERSA™ Fentanyl is manufactured at Kindeva's transdermal manufacturing facility in the United States.
The next step involves manufacturing clinical supplies and filing an Investigational New Drug (IND) application with the FDA to initiate a human abuse liability clinical study. Completing the commercial manufacturing scale-up is an important step towards the development of a commercially viable product and eventual NDA filing.
This achievement demonstrates the compatibility of the AVERSA™ abuse deterrent platform technology with established transdermal patch manufacturing processes. This milestone de-risks a significant aspect of the product's path to market and validates its scalability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.